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doi:10.1016/j.ejvs.2009.03.031Abstract Objective: Neovascularisation is a major cause of recurrent varicosities following
surgery. This prospective cohort study compares recurrence rates and the occurrence of neo-
vascularisation following surgery or endovenous laser ablation (EVLA) for great saphenous vein
reflux.
Method: 118 consecutive patients (72 female, 46 male, median age 48 [range 32e68 years]),
129 limbs were reviewed at a median of 24 months (range 18e30) after surgery (nZ 60 limbs)
or EVLA (nZ 69 limbs) for primary sapheno-femoral and GSV reflux. Varicose vein recurrence,
ultrasound detected groin neovascularisation and patient satisfaction (visual analogue scale)
were recorded.
Results: Recurrence rates at 2 years were: surgery group 4/60 (6.6%; mid-thigh perforator
nZ 2, residual GSV with neovascularisation nZ 2), EVLA group 5/69 (7%; GSV recanalisation
nZ 3 (all received <50 J/cm laser energy), mid-thigh perforator nZ 1, new anterior saphe-
nous vein reflux nZ 1) pZ 0.631. Neovascularisation was detected in 11/60 (18%) of the
surgery group and 1/69 (1%) of the EVLA group, pZ 0.001. Patient satisfaction rates were
90% and 88% respectively (pZ 0.37).
Conclusions: Although the frequency of recurrent varicosities 2 years after surgery and EVLA
was similar, neovascularisation, a predictor of future recurrence, was less common following
EVLA. Further, current recommendations on delivering 70 J/cm laser energy should reduce
recanalisation rates and recurrence after EVLA.
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Varicose vein recurrence is common following conventional
great saphenous vein (GSV) surgery, occurring in 13e29% of
patients.1e3 About twenty percent of interventions for
varicose veins are for recurrent varicosities after surgery.4,5
Although the causes of recurrence include perforator
incompetence, accessory vein reflux and inadequate
primary surgery, groin neovascularisation is the commonest
of these.2
Currently, there is increasing interest in the use of
minimally invasive treatments for varicose veins, including
foam sclerotherapy, radiofrequency and endovenous laser
ablation. Critics of these techniques suggest that recur-
rence rates may be higher than that those for conventional
surgery. The aim of the current prospective cohort study
was to compare both recurrence and neovascularisation
rates 2 years following either conventional surgical treat-
ment or endovenous laser ablation (EVLA) for varicose
veins.
Methods
Patients
The study was approved by our institutional ethics
committee and informed written consent was obtained
from patients. Consecutive patients undergoing treatment
for primary varicose veins due to sapheno-femoral (SFJ) and
great saphenous vein (GSV) reflux between January 2004
and May 2005 were suitable for either surgery or EVLA were
included in this study, 68 of whom were enrolled in
a randomised controlled trial comparing surgery with EVLA.
The remainder declined randomisation but were treated
contemporaneously and agreed to follow-up. Patients with
a previous deep vein thrombosis, recurrent varicose veins,
and those who had reflux in other axial veins (anterior
accessory great saphenous vein, small saphenous vein) or
perforators were excluded from the study.
Of 127 patients undergoing treatment, 118 (129 limbs, 72
female patients, 46 male, median age 48 [32e68]) have
completed 2-year follow-up: conventional surgery (60 limbs)
and EVLA (69 limbs).
Surgery
Surgical treatment was performed by a consultant vascular
surgeon under general anaesthesia. A flush sapheno-
femoral (SFJ) ligation was performed with ligation and
division of all tributaries together with GSV stripping to
the knee and multiple avulsions. No additional surgical
strategies such as a groin patch or over-sewing of the
saphenous trunk were used.
EVLA
EVLA was performed as described previously6 (810 nm diode
pulsed laser at 12 W power) by a consultant vascular
surgeon or a research registrar. The GSV was ablated from
the knee to the SFJ. Total laser energy (J) and energy
density (J/cm) were recorded prospectively. At 6- and12-weeks follow-up, residual superficial varicosities that
were either visible or palpable and >3 mm in size were
treated with foam sclerotherapy. Ultrasound guided foam
sclerotherapy for persisting or recurrent GSV reflux was not
performed during this study. The ‘‘package’’ of EVLA
together with delayed sclerotherapy (when required)
within 12 weeks of treatment achieves the same outcome
as conventional surgery.
Data collection and follow-up
Pre-treatment clinical severity (CEAP) scores and treatment
details were recorded prospectively. All patients underwent
both clinical examination and a duplex ultrasound scan
(DUS) using a TITAN ultrasound system (Sonosite Inc.,
Bothell, USA) before treatment and at 6, 12, 52 and 104
weeks after the treatment. The maximum diameter of the
GSV was measured using ultrasound (avoiding focal dilata-
tions due to varicosities) while standing prior to the treat-
ment. The reflux status of the SFJ, the treated GSV, the deep
veins and all axial veins were documented in each visit. If
visible, compressibility and detectable blood flow during
calf squeeze and release of the treated GSV were also
recorded at all follow-ups. Finally at 2 years patients were
examined for evidence of recurrent varicose veins. This was
defined as the presence of any visible or palpable varicosi-
ties measuring >3 mm on the treated leg that had been
noticed by the patient or the examining clinician.
Neovascularisation (serpentine venous channels) in the
groin was also identified by careful DUS assessment, with
the probe held longitudinally, horizontally and at different
angles. The largest diameter and the duration of reflux in
these channels were documented. When present, neo-
vascularisation was classified7 as those of small size
(<4 mm) with reflux of <1 s duration (Grade 1) and those
with larger (4 mm) veins and prolonged reflux (>1 s;
Grade 2). All recurrent varicosities were traced with DUS to
identify the source of reflux including thigh or calf perfo-
rators. Patients’ satisfaction scores at 2 years were
obtained using a visual analogue scale.
Statistical analysis
Recurrence and neovascularisation rates were compared
between groups using Fisher’s exact test. Patients’ satis-
faction was compared using a ManneWhitney U test. A p
value of <0.05 was considered significant. All analysis were
performed using the statistical package SPSS for Windows
(SPSS, Chicago, Illinois, USA).
Results
Patients’ demographic details and pre-treatment disease
severity are shown in Table 1. Recurrence and neo-
vascularisation rates are compared in Table 2. At one year
clinical recurrence was found in 2 surgical and 5 EVLA
patients with groin neovascularisation present in 7 and 1
patients respectively.
At 2 years neovascularisation was detected in 11/60
(18%) patients following surgery and 1/69 (1%) after EVLA
(pZ 0.001). Of the patients with neovascularisation 6/11
Table 1 Base line characteristics of study patients
Surgery EVLA p
Age: median (inter-
quartile range, IQR)
46 (32e60) 49 (30e78) 0.43
Male: Female 39:21 45:22 0.49
Previous DVT 0 0 e
Pre-treatment C of CEAPa
Number of limbs 64 73
C2 39 43 0.42
C3 12 13
C4 12 14
C5/6 1 3
GSV diameter (mm)b
median (IQR)
7.8 (5.8e9.1) 8.1 (5.9e9.3) 0.24
a Pre-treatment C of CEAP classification (EAP of CEAP was the
same in all patients e see exclusion criteria).
b Maximum diameter with patient standing, avoiding focal
dilatations.
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group whilst a single patient in the EVLA group had Grade 2
neovascularisation. Overall clinically apparent, cumulative
recurrence rates up to 2 years were 4/60 (6.6%) and 5/69
(7%) following surgery and EVLA respectively (pZ 0.631).
Following surgery, 2 patients developed recurrence due to
an incompetent thigh perforator by 1 year and 2 were due to
neovascularisation promoting reflux in a persisting, incompe-
tent, segment of GSV (inadequate stripping) at 2 years. A
further 9patients showedevidenceof groin neovascularisation
on DUS but without clinical recurrence at 2 years.
All recurrences in the EVLA group were evident at one
year with 3/5 (60%) following early GSV recanalisation by 12
weeks. These patients all received <50 J/cm laser energy
during EVLA. Of these 3, one patient also had Grade 2
neovascularisation associated with GSV recanalisation. TheTable 2 Comparison of recurrence patterns and neo-
vascularisation rates between groups treated by conven-
tional surgery or EVLA
1-year follow-up
(nZ limbs)
Surgery
(nZ 63)
EVLA
(nZ 71)
p
Clinical recurrence 2/63 (3%) 5/71 (7%)
Incompetent perforator 2 (3%) 1 (1%)
Recanalisation/residual
GSV
2 (3%) 3 (4%)
Reflux into the AAGSVa 0 e 1 (1%)
Neovascularisation 7/63 (11%) 1/71 (1%)
2-years follow-up
(nZ limbs)
Surgery
(nZ 60)
EVLA
(nZ 69)
p
Clinical recurrence 4/60 (7%) 5/69 (7%) 0.44
Incompetent perforator 2 (3%) 1 (1%) 0.45
Recanalisation/residual
GSV
2 (3%) 3 (4%) 0.36
Reflux into the AAGSV 0 e 1 (1%) 0.53
Neovascularisation 11/60 (18%) 1/69 (1%) 0.001
a AAGSV: anterior accessory great saphenous vein.remaining 2/5 (40%) recurrences were due to an incompe-
tent mid-thigh perforator (nZ 1), and reflux into the
anterior accessory great saphenous vein (AAGSV, nZ 1).
At 2 years, patients’ satisfaction rates were 90% and 88%
in the surgery and EVLA groups respectively (pZ 0.37).
Two patients in the EVLA group had an active venous
ulcer prior to the treatment. Two further patients (one
from each group) had healed ulcers at the time of initial
treatment. The active ulcers had healed by 12 weeks and
by 6 months respectively and all remained healed at 2-year
follow-up.
Discussion
Overall the recurrence rates for both conventional surgery
and EVLA were similar 2 years after treatment. However,
DUS detected groin neovascularisation was more common
following surgery compared to EVLA. Thus, most recur-
rences following EVLA reflected inadequate primary treat-
ment and it is likely that these could have been prevented
by the administration of 70 J/cm laser energy to the
vein.6 The different patterns of recurrence following EVLA
and surgery are depicted in Figs. 1 and 2.
Varying frequencies (8e60%)7e12 of neovascularisation
have been reported after surgerywhich probably reflects the
differing duration of follow-up, surgical technique, and the
sensitivity of DUS and the operator. Neovascularisation was
detected in 18% (11/60) of limbs treated surgically in this
series with 5/11 (45%) having Grade 2 neovascularisation
which may be associated with a higher risk of recurrence.
Although clinically obvious recurrence was not documented
in most patients, Maeseneer et al.7 have shown that neo-
vascularisation rates at 1 year predict the development of
clinical recurrence at 5 years. This reflects the likelihood
that clinically obvious recurrence may take longer to
develop, particularly in patients in whom the GSV has been
adequately stripped, when secondary to neovascularisation.Selective laser ablation of GSV Possible patterns of recurrence after EVLA 
1
3
2
FV FV
Ablated GSV 
SFJ SFJ 
AAGSV
Figure 1 Possible patterns of reflux after EVLA (FV e femoral
vein). 1: Recanalisation. 2: Neo-reflux into AAGSV. 3: Incom-
petent perforating vein.
Surgical high tie
and stripping
Possible patterns of recurrence
following surgery
SFJ
PV
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FV
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4
3
2
Stripped GSV
FV
Figure 2 Patterns of reflux after surgery. 1: Neovascularisation.
2: Incompetent perforating vein. 3: Persisting GSV/new vessel
formation. 4: Para-reflux connecting via neovascularisation.
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vascularisation is the result of angiogenesis following
surgery11 and modified techniques such as over-sewing the
stump may reduce the risk of neovascularisation12 although
the use of a PTFE patch to separate the SFJ from the GSV
tract did not prove successful.13
Since EVLA ablates the target vein within, extra-venous
tissue injury is minimal and neovascularisation should not
occur. However one patient in this series developed neo-
vascularisation following laser therapy and it is logical to
suggest that this was the result of vein wall perforation and
haematoma formation. This advantage has also been
reported following radiofrequency ablation14 although
there are no studies examining its frequency following DUS
guided foam sclerotherapy.
Residual varicosities that persist after EVLA should be
differentiated from recurrent varicose veins. The extent of
residual varicosities depends on the pre-treatment
anatomical distribution of varicosities and their haemody-
namic relationship with the incompetent axial vein. Vari-
cosities that are directly connected to the incompetent
axial vein tend to shrink when this is ablated both below
and above their origin. In contrast, varicosities that cross
communicate with other ‘‘feeding’’ veins tend to remain as
residual varicosities. A previous study has shown that
ablation of the GSV from below the lowest point of axial
vein reflux results in a 4-fold reduction in the requirement
for delayed foam sclerotherapy (61e17%).15
Following ablation of a single incompetent axial vein,
neo-reflux into another axial vein, is theoretically possible.
This occurred in one patient who developed AASV reflux
following GSV laser ablation. This could represent either
neo-reflux or failure of pre-treatment DUS to demonstrate
reflux into the ASV. The latter may be more likely since
previous studies have shown that SFJ tributaries remain
competent following selective EVLA of incompetent axial
veins.16,17
Recanalisation occurs in up to 4% of axial veins after
EVLA, although most are not associated with recurrent
varicose veins unless it occurs within 6 weeks of treatment
(primary treatment failure).18 When recanalisation occursearly it is almost always associated with low energy densi-
ties (<60 J/cm). Given the current recommendation to
employ 70 J/cm, it is anticipated that this type of
recurrence will be uncommon in the future.6
A combination of neovascularisation and a residual
segment of incompetent GSV led to recurrence in 2 patients
in the surgery group reflecting the importance of ensuring
that stripping is complete. Whilst this is not generally
confirmed during surgery EVLA is performed under ultra-
sound control which should guarantee this. Although
increasing sub-specialisation within general surgery should
make inadequate surgery a less likely cause of recurrent
varicose veins,19,20 outcomes might be improved by
employing DUS to confirm complete GSV stripping.
Incompetent perforating veinswere a cause of recurrence
following both operation and EVLA and may be the principle
aetiological factor in up to 14% of patients with recurrent
varicose veins following surgery.21 This pattern of refluxmay
occur following neovascularisation within strip-tract hae-
matoma or after incomplete stripping of the incompetent
axial vein. It is therefore important that pre-treatment
imaging identifies any perforators and that stripping or laser
ablation is performed from the groin to a point distal to the
perforating vein. In this respect, a potential advantage of
EVLA is the ability to ablate an incompetent GSV beyond
possible sites of perforating veins such as Boyd’s perforators
in the proximal calf without a significant risk of saphenous
nerve injury15 which commonly occurs following surgical
stripping.
One criticism of this study is that it was of a prospective
cohort design rather than an RCT although it did include
patients from a previous randomised trial comparing EVLA
and surgery22 provided that they had attended for 2-year
follow-up. In the randomised trial only 136 patients were
successfully recruited after screening 534 patients (177
preferring a specific method of treatment (usually EVLA)
and 221 not meeting the inclusion criteria). It was not
considered practical to perform a second RCT to answer the
important questions answered by the current study within
a reasonable time frame.
In conclusion, different patterns of recurrence occur
after EVLA and surgery. Although the overall recurrence
rates for both techniques were similar at 2-year follow-up
it is probable that recanalisation after laser ablation can
be minimised by modifying laser energy delivery. In
contrast neovascularisation is likely to remain a significant
problem following conventional surgery although more
widespread use of careful ultrasound assessment might
ensure more successful stripping of the GSV and any
associated incompetent axial veins. Nevertheless the very
low incidence of neovascularisation following EVLA
suggests that recurrence rates may be lower with this
technique.
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